TW202146010A - 原發性腋窩多汗症的治療方法及其醫藥 - Google Patents
原發性腋窩多汗症的治療方法及其醫藥 Download PDFInfo
- Publication number
- TW202146010A TW202146010A TW110107310A TW110107310A TW202146010A TW 202146010 A TW202146010 A TW 202146010A TW 110107310 A TW110107310 A TW 110107310A TW 110107310 A TW110107310 A TW 110107310A TW 202146010 A TW202146010 A TW 202146010A
- Authority
- TW
- Taiwan
- Prior art keywords
- treatment
- preparation
- armpits
- bromide
- primary axillary
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 30
- 239000003814 drug Substances 0.000 title description 20
- 238000011282 treatment Methods 0.000 claims abstract description 174
- 238000002360 preparation method Methods 0.000 claims abstract description 115
- 208000008454 Hyperhidrosis Diseases 0.000 claims abstract description 80
- 230000036617 axillary hyperhidrosis Effects 0.000 claims abstract description 70
- 230000035900 sweating Effects 0.000 claims abstract description 49
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 32
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 21
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 claims description 12
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 5
- 229940051250 hexylene glycol Drugs 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 210000001099 axilla Anatomy 0.000 abstract description 3
- 238000000892 gravimetry Methods 0.000 abstract description 2
- FIAFMTCUJCWADZ-WVXMCOPUSA-M [(1r,3r)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N@@+](CC(=O)OCC)(C)CC[C@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 FIAFMTCUJCWADZ-WVXMCOPUSA-M 0.000 abstract 1
- 229950008610 sofpironium bromide Drugs 0.000 abstract 1
- 210000004243 sweat Anatomy 0.000 description 44
- 238000012360 testing method Methods 0.000 description 42
- 230000037315 hyperhidrosis Effects 0.000 description 31
- 238000009472 formulation Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- FIAFMTCUJCWADZ-JOFREBOKSA-M [(3r)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](CC(=O)OCC)(C)CC[C@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 FIAFMTCUJCWADZ-JOFREBOKSA-M 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000000812 cholinergic antagonist Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000000106 sweat gland Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 4
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 4
- 238000000546 chi-square test Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 ester compound Chemical class 0.000 description 3
- 229960002462 glycopyrronium bromide Drugs 0.000 description 3
- 208000001875 irritant dermatitis Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940089093 botox Drugs 0.000 description 2
- 229940094657 botulinum toxin type a Drugs 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000013094 purity test Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000028048 Accommodation disease Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 206010066419 Compensatory sweating Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- XLBIBBZXLMYSFF-UHFFFAOYSA-M Propantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 XLBIBBZXLMYSFF-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000037391 generalized hyperhidrosis Effects 0.000 description 1
- 208000012155 generalized hyperhidrosis Diseases 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940099209 probanthine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020035828 | 2020-03-03 | ||
| JP2020-035828 | 2020-03-03 | ||
| JP2020-147340 | 2020-09-02 | ||
| JP2020147340 | 2020-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202146010A true TW202146010A (zh) | 2021-12-16 |
Family
ID=77613052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110107310A TW202146010A (zh) | 2020-03-03 | 2021-03-02 | 原發性腋窩多汗症的治療方法及其醫藥 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPWO2021177257A1 (enrdf_load_stackoverflow) |
| KR (1) | KR20220149551A (enrdf_load_stackoverflow) |
| TW (1) | TW202146010A (enrdf_load_stackoverflow) |
| WO (1) | WO2021177257A1 (enrdf_load_stackoverflow) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9220707B2 (en) | 2013-03-15 | 2015-12-29 | Bodor Laboratories, Inc. | Method of dosing and use of soft anticholinergic esters |
| US20150259283A1 (en) | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| CN119033771A (zh) | 2015-07-21 | 2024-11-29 | 博多尔实验仪器公司 | 软性抗胆碱能药类似物的制剂 |
| TWI719046B (zh) | 2016-07-21 | 2021-02-21 | 美商波德實驗股份有限公司 | 軟性抗膽鹼類似物之製劑 |
-
2021
- 2021-03-02 JP JP2022504369A patent/JPWO2021177257A1/ja active Pending
- 2021-03-02 WO PCT/JP2021/007791 patent/WO2021177257A1/ja active Application Filing
- 2021-03-02 TW TW110107310A patent/TW202146010A/zh unknown
- 2021-03-02 KR KR1020227032655A patent/KR20220149551A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220149551A (ko) | 2022-11-08 |
| JPWO2021177257A1 (enrdf_load_stackoverflow) | 2021-09-10 |
| WO2021177257A1 (ja) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Borobia et al. | Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: InMEDIATE: a randomized controlled trial in emergency departments | |
| JP4898073B2 (ja) | 鼻内投与用フェンタニル組成物 | |
| Lockey et al. | Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes | |
| JP2008542324A (ja) | 医療用デバイスおよび医薬製剤において有用な粘膜付着性キシログルカン含有製剤 | |
| JP7264813B2 (ja) | 末梢神経障害性疼痛の治療に使用するための局所作用用フェニトイン | |
| EP2568806B1 (en) | Therapeutic regimens | |
| ES2825799T3 (es) | Formulaciones en gel de testosterona intranasal de concentración de dosis más baja y uso de las mismas para tratar anorgasmia o trastorno del deseo sexual hipoactivo | |
| Scheinfeld | Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents | |
| Umpreecha et al. | Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial | |
| WO2012142145A1 (en) | Methods of treating skin conditions exhibiting telangiectasia | |
| Lipworth et al. | A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol | |
| US10716779B2 (en) | Methods and compositions for treating foot or hand pain | |
| WO2011019732A1 (en) | Methods for iontophoretically treating nausea and migraine | |
| Salehi et al. | Evaluation of caffeic acid mucoadhesive tablets on minor recurrent aphthous stomatitis: a randomized, double-blind, placebo-controlled clinical trial | |
| Kuna et al. | Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma | |
| JP2024522808A (ja) | ゴーリン症候群を治療するための方法および組成物 | |
| TW202146010A (zh) | 原發性腋窩多汗症的治療方法及其醫藥 | |
| M Farber et al. | Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson’s disease | |
| US20250228825A1 (en) | Compositions of rapamycin and their use in the treatment of microcystic lymphatic malformation | |
| WO2024227098A1 (en) | Halobetasol propionate-lidocaine formulations | |
| TW202502329A (zh) | 用於治療脊髓性肌萎縮的組成物及方法 | |
| WO2015172102A1 (en) | Treating female sexual arousal disorder and related symptoms | |
| JPH04159224A (ja) | ヒトの糖尿病性知覚障害および末梢神経障害の治療剤 | |
| Erickson et al. | Compounded analgesic therapy for disorders of movement: arthritis, neuropathic pain, and postpolio syndrome | |
| CN120152984A (zh) | 治疗和/或预防日光性角化病的化合物及方法 |